Outcome and long-term effects of pregnancy in women with hyperprolactinaemia. 1992

X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
Department of Endocrinology and Nutrition, Hospital de la Santa Cruz y San Pablo, Autonomous University, Barcelona, Spain.

Twenty-four women with high circulating prolactin became pregnant on 39 occasions, of which 32 ended in delivery. Sixteen patients showed radiological evidence of pituitary tumour, 6 exhibited a normal CT and 2 had an empty sella. The pregnancies were induced in 4 patients after successful pituitary surgery, in 3 after surgery and medical treatment, and in the rest by bromocriptine (16) long-acting repeatable bromocriptine (1) and methergoline (1). No major complications related to hyperprolactinaemia or its treatment were observed during pregnancy in the patients or offspring. Prolactin after pregnancy was lower than before (basal 95 micrograms/l, after 1st pregnancy 38 micrograms/l P < 0.002, after 2nd pregnancy 24 micrograms/l P < 0.005 compared to basal prolactin); this prolactin reduction tended to be greater in the 9 multiparous patients, but did not attain statistical significance, probably because the number of multiparous patients was too small. A new empty sella developed after delivery in 4 women and persisted in another 2, all of which were medically treated; prolactin fell in all 6 cases normalizing in 3; 4 of these patients had undergone two or more pregnancies. The mean period of follow-up from the last pregnancy was 41.6 months (8-101). These data suggest that pregnancy may hasten a tendency to spontaneous improvement of hyperprolactinaemia, and multiparity may be beneficial in this way.

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D010062 Ovulation Induction Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum. Ovarian Stimulation,Ovarian Stimulations,Stimulation, Ovarian,Stimulations, Ovarian
D010298 Parity The number of offspring a female has borne. It is contrasted with GRAVIDITY, which refers to the number of pregnancies, regardless of outcome. Multiparity,Nulliparity,Primiparity,Parity Progression Ratio,Parity Progression Ratios,Ratio, Parity Progression,Ratios, Parity Progression
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011248 Pregnancy Complications Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. Adverse Birth Outcomes,Complications, Pregnancy,Adverse Birth Outcome,Birth Outcome, Adverse,Complication, Pregnancy,Outcome, Adverse Birth,Pregnancy Complication
D011256 Pregnancy Outcome Results of conception and ensuing pregnancy, including LIVE BIRTH; STILLBIRTH; or SPONTANEOUS ABORTION. The outcome may follow natural or artificial insemination or any of the various ASSISTED REPRODUCTIVE TECHNIQUES, such as EMBRYO TRANSFER or FERTILIZATION IN VITRO. Outcome, Pregnancy,Outcomes, Pregnancy,Pregnancy Outcomes
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004652 Empty Sella Syndrome A condition when the SELLA TURCICA is not filled with pituitary tissue. The pituitary gland is either compressed, atrophied, or removed. There are two types: (1) primary empty sella is due a defect in the sella diaphragm leading to arachnoid herniation into the sellar space; (2) secondary empty sella is associated with the removal or treatment of PITUITARY NEOPLASMS. Empty Sella Syndrome, Primary,Empty Sella Syndrome, Secondary,Empty Sella Turcica,Empty Sella Turcica Syndrome,Primary Empty Sella Syndrome,Secondary Empty Sella Syndrome,Empty Sella Syndromes,Empty Sella Turcicas,Sella Turcica, Empty,Sella Turcicas, Empty
D005260 Female Females

Related Publications

X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
August 2003, The New Zealand medical journal,
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
October 1997, Journal of endocrinological investigation,
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
June 1980, Clinical endocrinology,
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
September 1996, Clinical endocrinology,
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
May 1987, Irish medical journal,
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
January 2015, Human reproduction (Oxford, England),
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
September 1988, Clinical endocrinology,
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
September 1981, Lancet (London, England),
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
November 2018, The American journal of cardiology,
X Ampudia, and M Puig-Domingo, and D Schwarzstein, and R Corcoy, and J J Espinós, and J Calaf-Alsina, and S M Webb
January 1990, Upsala journal of medical sciences,
Copied contents to your clipboard!